Michael Gelband’s Castle Biosciences CSTL Stock Holding History

Michael Gelband’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21,100	Closed	-$1.41M	–	2182
2020 Q4	$1.41M	Buy	+21,100	New	+$1.14M	0.01%	690

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's CSTL Position: Q2 2026 in Review

Michael Gelband sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 32,608 shares — an estimated $801K sold.

Michael Gelband first reported a position in CSTL in Q2 2020 and held it in 8 quarters. The position peaked at $1.55M in Q1 2025. 175 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Michael Gelband reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 32,608 Castle Biosciences shares in Q2 2026, an estimated $801K.
Michael Gelband first reported a position in Castle Biosciences in Q2 2020 and held it in 8 quarters.
Michael Gelband's Castle Biosciences position peaked at $1.55M in Q1 2025.
175 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.